These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 19069460)
1. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea]. Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460 [TBL] [Abstract][Full Text] [Related]
2. The prevalence of small intestinal bacterial vergrowth in irritable bowel syndrome. Mann NS; Limoges-Gonzales M Hepatogastroenterology; 2009; 56(91-92):718-21. PubMed ID: 19621689 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. Chang FY; Lu CL; Chen CY; Luo JC J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369 [TBL] [Abstract][Full Text] [Related]
4. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790 [TBL] [Abstract][Full Text] [Related]
5. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). Khalif IL; Quigley EM; Makarchuk PA; Golovenko OV; Podmarenkova LF; Dzhanayev YA J Gastrointestin Liver Dis; 2009 Mar; 18(1):17-22. PubMed ID: 19337628 [TBL] [Abstract][Full Text] [Related]
6. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease]. Maev IV; Samsonov AA; Golubev NN Klin Med (Mosk); 2008; 86(9):57-63. PubMed ID: 19048841 [TBL] [Abstract][Full Text] [Related]
7. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234 [TBL] [Abstract][Full Text] [Related]
8. Treatment of irritable bowel syndrome. A case control experience. Astegiano M; Pellicano R; Terzi E; Simondi D; Rizzetto M Minerva Gastroenterol Dietol; 2006 Dec; 52(4):359-63. PubMed ID: 17108865 [TBL] [Abstract][Full Text] [Related]
9. [Irritated bowel syndrome: clinicomorphological aspects of treatment with melaxen]. Komarov FI; Raĭkhlin NT; Rapoport SI; Malinovskaia NK; Voznesenskaia LA; Rumiantseva AI Klin Med (Mosk); 2006; 84(11):30-6. PubMed ID: 17243607 [TBL] [Abstract][Full Text] [Related]
10. A controlled clinical trial with De-Nol (tripotassium dicitrato bismuthate) in patients with gastric ulcer. Patty I; Deák G; Jávor T; Mózsik G; Nagy L; Tárnok F Int J Tissue React; 1983; 5(4):397-401. PubMed ID: 6368445 [TBL] [Abstract][Full Text] [Related]
12. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Cappello G; Spezzaferro M; Grossi L; Manzoli L; Marzio L Dig Liver Dis; 2007 Jun; 39(6):530-6. PubMed ID: 17420159 [TBL] [Abstract][Full Text] [Related]
13. Bacterial concepts in irritable bowel syndrome. Lin HC; Pimentel M Rev Gastroenterol Disord; 2005; 5 Suppl 3():S3-9. PubMed ID: 17713456 [TBL] [Abstract][Full Text] [Related]
14. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Cremon C; Gargano L; Morselli-Labate AM; Santini D; Cogliandro RF; De Giorgio R; Stanghellini V; Corinaldesi R; Barbara G Am J Gastroenterol; 2009 Feb; 104(2):392-400. PubMed ID: 19174797 [TBL] [Abstract][Full Text] [Related]
15. De-Nol in the treatment of reflux esophagitis. Balan G; Săndulescu E; Cijevschi C; Stanciu R; Darwish R; Stanciu C Rev Med Chir Soc Med Nat Iasi; 1989; 93(1):67-70. PubMed ID: 2682898 [TBL] [Abstract][Full Text] [Related]
16. [Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs]. Maev IV; V'iuchnova ES; Staseva IV Ter Arkh; 2004; 76(2):27-30. PubMed ID: 15106410 [TBL] [Abstract][Full Text] [Related]
17. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702 [TBL] [Abstract][Full Text] [Related]
18. Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal pain, diarrhea and other signs and symptoms (CEDAP-Plus Study). May A; Manner H; Schneider M; Ipsen A; Ell C Endoscopy; 2007 Jul; 39(7):606-12. PubMed ID: 17611915 [TBL] [Abstract][Full Text] [Related]
19. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974 [TBL] [Abstract][Full Text] [Related]
20. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome? Stoicescu A; Andrei M; Becheanu G; Stoicescu M; Nicolaie T; Diculescu M Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):766-72. PubMed ID: 23272525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]